The role of prolactin/vasoinhibins in cardiovascular diseases

被引：3

作者：

Zhao, Hui ^{[1
,2
,3
]}

Gong, Sugang ^{[3
]}

Shi, Yongcong ^{[4
]}

Luo, Cijun ^{[3
]}

Qiu, Hongling ^{[3
]}

He, Jing ^{[3
]}

Sun, Yuanyuan ^{[3
]}

Huang, Yuxia ^{[3
]}

Wang, Shang ^{[3
]}

Miao, Yuqing ^{[1
,2
]}

Wu, Wenhui ^{[3
]}

机构：

[1] Univ Shanghai Sci & Technol, Sch Mat & Chem, Shanghai 200093, Peoples R China

[2] Univ Shanghai Sci & Technol, Inst Bismuth & Rhenium, Shanghai 200093, Peoples R China

[3] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Cardiopulm Circulat, 507 Zhengmin Rd, Shanghai 200433, Peoples R China

[4] Dongchuan Dist Peoples Hosp, Resp Med, Kunming, Yunnan, Peoples R China

来源：

ANIMAL MODELS AND EXPERIMENTAL MEDICINE | 2023年 / 6卷 / 02期

基金：

上海市自然科学基金; 中国国家自然科学基金;

关键词：

cardiovascular diseases; endothelial cells; prolactin; vasoinhibins; SERUM PROLACTIN CONCENTRATIONS; ENDOTHELIAL-CELLS; PERIPARTUM CARDIOMYOPATHY; PRECLINICAL ATHEROSCLEROSIS; CATHEPSIN-D; 16K PRL; RISK; SECRETION; DYSFUNCTION; EXPRESSION;

D O I：

10.1002/ame2.12264

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Prolactin (PRL) is a polypeptide hormone that is mainly synthesized and secreted by the lactotroph cells of the pituitary. There are two main isoforms of PRL: 23-kDa PRL (named full-length PRL) and vasoinhibins (including 5.6-18 kDa fragments). Both act as circulating hormones and cytokines to stimulate or inhibit vascular formation at different stages and neovascularization, including endothelial cell proliferation and migration, protease production, and apoptosis. However, their effects on vascular function and cardiovascular diseases are different or even contrary. In addition to the structure, secretion regulation, and signal transduction of PRL/vasoinhibins, this review focuses on the pathological mechanism and clinical significance of PRL/vasoinhibins in cardiovascular diseases.

引用

页码：81 / 91

页数：11

共 50 条

[41] The role of the inflammasome in cardiovascular diseases
Li, Xuan
Deroide, Nicolas
Mallat, Ziad
JOURNAL OF MOLECULAR MEDICINE-JMM, 2014, 92 (04): : 307 - 319
[42] The role of the inflammasome in cardiovascular diseases
Xuan Li
Nicolas Deroide
Ziad Mallat
Journal of Molecular Medicine, 2014, 92 : 307 - 319
[43] Role of oxylipins in cardiovascular diseases
Mohammed A Nayeem
Acta Pharmacologica Sinica, 2018, 39 : 1142 - 1154
[44] Molecular Mechanisms and Promising Role of Dihydromyricetin in Cardiovascular Diseases
Nie, Hao
Ji, Tianyi
Fu, Yu
Chen, Danyang
Tang, Zhouping
Zhang, Cuntai
PHYSIOLOGICAL RESEARCH, 2022, 71 (06) : 749 - 762
[45] Role of Exosomes in Cardiovascular Diseases
Lin, Qiumei
He, Pingfeng
Tao, Jing
Peng, Jing
REVIEWS IN CARDIOVASCULAR MEDICINE, 2024, 25 (06)
[46] The Emerging Role of MicroRNA-155 in Cardiovascular Diseases
Cao, Richard Y.
Li, Qing
Miao, Yi
Zhang, Ying
Yuan, Wenchao
Fan, Li
Liu, Gongliang
Mi, Qiongyao
Yang, Jian
BIOMED RESEARCH INTERNATIONAL, 2016, 2016
[47] Role of intestinal microbiota changes in cardiovascular diseases pathogenesis
Lyzohub, V. H.
Kramarova, V. N.
Melnychuk, I. O.
ZAPOROZHYE MEDICAL JOURNAL, 2019, 21 (05) : 672 - 678
[48] Therapeutic Effects of Traditional Chinese Medicine on Cardiovascular Diseases: the Central Role of Calcium Signaling
Li, Yuxin
Zhang, Zhang
Li, Sen
Yu, Tingting
Jia, Zhaoqi
FRONTIERS IN PHARMACOLOGY, 2021, 12
[49] The emerging role of interleukin-37 in cardiovascular diseases
Zhuang, Xinyu
Wu, Bangwei
Li, Jian
Shi, Haiming
Jin, Bo
Luo, Xinping
IMMUNITY INFLAMMATION AND DISEASE, 2017, 5 (03) : 373 - 379
[50] The role of hypoxia-inducible factors in cardiovascular diseases
Yu, Baoqi
Wang, Xia
Song, Yanting
Xie, Guomin
Jiao, Shiyu
Shi, Li
Cao, Xuejie
Han, Xinyao
Qu, Aijuan
PHARMACOLOGY & THERAPEUTICS, 2022, 238

← 1 2 3 4 5 →